Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Baxter International has entered into an agreement to acquire Inspiration BioPharmaceuticals' investigational hemophilia compound OBI-1 and related assets.
Subscribe to our email newsletter
Baxter said, in conjunction with Inspiration’s ongoing bankruptcy proceedings, it will also acquire certain other OBI-1 related assets including manufacturing operations from Ipsen Pharma.
Recombinant porcine factor VIII (rpFVIII) OBI-1, which is currently in Phase III clinical studies, is being investigated for the treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors.
The transaction is subject to bankruptcy court and regulatory approvals.
Under the terms of the agreement, Baxter will make an upfront payment of $50m for the OBI-1 assets, including the manufacturing operations.
In addition, Baxter will pay in the future up to $20m based on regulatory approval of the acquired hemophilia A indication in the US and first additional country.
Baxter will also pay additional amounts, upon approval of additional indications, through net sales payments, and as sales milestones when sales exceed $100m.
OBI-1 received orphan drug designation in the US and Europe, and was granted fast track designation for acquired hemophilia A by the US Food and Drug Administration (FDA).